CAPTIVATE: Primary Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL

June 4-8, 2021; Online at
In patients with previously untreated CLL/SLL, fixed-duration treatment of ibrutinib plus venetoclax resulted in deep and durable responses with high rates of treatment completion.
Format: Microsoft PowerPoint (.ppt)
File Size: 409 KB
Released: June 11, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

In this video from Clinical Care Options (CCO), Drs Michael Bishop, Jesús Berdeja, and Jae Park discuss key data on CAR T-cell therapy

Michael R. Bishop, MD
Program Director
person default Jesús G. Berdeja, MD Jae H. Park, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: January 13, 2022 Expired: January 12, 2023

Downloadable PDF resource guide with key information and resources for optimal management of patients with CML using TKIs, from clinical care options (CCO)

person default Caitlin R. Rausch, PharmD Released: January 12, 2022

PDF resource that serves as a helpful guide for healthcare professionals on BTK inhibitors in B-cell lymphoma, from Clinical Care Options (CCO)

Released: January 4, 2022

Short downloadable slideset on clinical insights on treatment for B-cell lymphomas, from Clinical Care Options (CCO).

Brad S. Kahl, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: January 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings